内容发布更新时间 : 2024/5/11 16:35:17星期一 下面是文章的全部内容请认真阅读。
Research report -An analysis and evaluation of the business and financial performance of an organisation over a three year period
1. Reasons for choosing topic and organisation:
In recent years, the medicine market demand continued to rise in the end of the scale. The pharmaceutical industry has sustained high growth in these years.National hospital terminal purchase market size reached about 246 billion in every country. The scale of the drug market will be up to 769.6 billion, accounted for ratio which can reach more than 60%. The income of traditional medicine is up to 384.8 billion, accounting for 30% in a way. The income ofbiological medicine is 86.9 billion, accounted for more than 7%. At the same time, in the recent years governments in health investment has increased year by year, 19980 billion from 2010 to 2014 36999.85 billion. Health expenditure in the GDP proportion is steadily improving.
The broad market capacity is the basic of economy development .Sustainable development of pharmaceutical industry in various countries in health industry market capacity of nearly 4500 billion in aspect of income in 2014, which the medical service market capacity is 2.14 billion, accounted for nearly 50%. The income of drug market capacity is about 40%. The income of the equipment accounted for 3%. Under the influence of drug price reform, medicine income accounted for than will gradually decline, medical services accounted for the ratio will be improved accordingly.
Pharmaceutical industry is growing faster than GDP. Since 2011, the pharmaceutical industry added value growth sustained higher than the overall level of national industrial (3% - 5%), far higher than the other industry and pharmaceutical industry in national industry accounted for ratio continues to increase, in 2007 which accounted for 1.5% to 2014 (2.2%).
But in recent years, the accident of the pharmaceutical industry is frequent, the policy landing is intensive, the future situation of the industry is uncertain. So we should how to develop it? Pharmaceutical enterprises how to face the new policy and make new adjustment? Facing the new a series of difficult problems, the pharmaceutical industry should do what to how to innovate, to lower the cost. At the same time,the pharmaceutical industryshould do what to supply drug demand of high quality to satisfy the people, how to deal with the contradiction between the doctor and the patient. These problems have attracted much attention.
Hikma group was founded in 1978 by SamihDarwazah, a multinational pharmaceutical company. The group early in the business strategy is mainly for the Middle East market production affixed with the trademark not registered drug. In the 1980s early, Hikma group on the basis of the original product, an increase of multinational pharmaceutical companies in the production of registered drug to supplement its sales and sending structure. Since then Hikma group has achieved rapid development, in the world established branch. At present, the group in the Middle East and North Africa, Europe and the United States has six branch, in Algeria and a company is under construction.
HikmaHikma pharmaceuticals company (Amman, Jordan) is the first group operating company for the Arab world was the first U. S. Food and Drug Administration (FDA) license in the United States sales of its pharmaceutical company. The company also won the UK medicines and Healthcare Products Management Agency (MHRA) license, you can in the UK drug sales. The company's main factory has a variety of functions, not only can save raw materials, but also can carry out research and development, but also the production of drugs and quality detection. In addition to the main outside the factory,
Hikma Jordan group company and active pharmaceutical ingredients (APIs) plant. The two factories by the U. S. Food and Drug Administration (FDA) for examination and approval.
Hikma group of strategic investments in the United States can be traced back to 1991, when the management of the group and seized the American pharmaceutical cooperation opportunity to enter the United States the largest unregistered drug market. At that time, West-ward pharmaceutical company to become the enterprise losses because there is no research institutions and narrow range of products, but also by the United States Food and Drug Administration (FDA) told to comply with the relevant provisions of the drug production. After the acquisition, Hikma group has appointed a new management team, through the establishment and
improvement of the company rules and regulations, management, sales and marketing research and management, to restructure the company. Due to the operation of the company management is very fruitful, in late 90s gradually improved.19952005 years that company has expanded several times, adding two buildings, a seat for packaging, administrative management, another for quality inspection, research and analysis of research. Because in compliance with drug Product management in the U.S. Food and drug administration has an excellent record, West-ward is considered to be the company's Hikma group, the company's largest contribution to the company's profits.
On the other hand, Hikma group through 1998 in Saudi Arabia established joint venture Jazeera pharmaceutical industry company (JPI) (Jordan and Saudi Arabia each accounted for 47.5% and 52.5% of the shares) to achieve the deployment strategy in Saudi Arabia. The company began production in 1999, has three factories: universal formula works, penicillin and cephalosporin factory, and has passed the approval of the Saudi Ministry of health and Slovakia drug control departments, is expected in 2005 before the end of the year to get the approval of the U. S. Food and drug administration. In 2004, as part of a restructuring of the group, Hikma group in New Jersey merged a new holding company, HikmaPharma Limited to replace the original Hikma Investment Co., Ltd. New holdings include all of the companies, but also includes the following companies: Arab medicine company (wholly owned Jordanian companies), HikmaPharma GmbH (Germany invested sales company), Sudan's PharmaIxir company (51% ownership), Hikma biotech S.A.S.U (French owned branch); also in Jordan and two research centers: International Pharmaceutical Research research centers and specialized medicine research center, Hikma group each accounted for 51% and 95% of the shares.
Hikma group to the diversity of product structure and covering 33 countries extensive sales network to send and become a diversified business model, not only reduced the risk management, and has become a backbone enterprises of the pharmaceutical industry. The group is now producing 138 kinds of products, 298 species different agent amount and forms, including their own products and licensing products and business scope includes not affixed trademarks of solid drugs is not registered, affixed with the trademark unregistered medicines and the development of new drugs and injection, treatment including anti infection,
cardiovascular diseases, musculoskeletal diseases, immune adjustment, gastrointestinal diseases and metabolism and nervous system diseases. The group is the development, production and sales of 36 solid
unidentified unregistered drug dose and form 79 different strong, last year 50.4% of net sales of the products revenue in the company. The group has 47 branded unregistered medicines and 18 kinds of new drugs, a total of 143 different dosages and forms, in 2004 revenue of $74 million, accounting for the company's net sales of 34.6%. injection in the group also produces 30 kinds of branded and non branded, 7 kinds of licensed products, 76 kinds of different dosages and forms, their income accounted for the company in 2004 net sales of 13.5%. products is the minimum injection group, a some of the latest fastest-growing. Due to the high threshold, so the global manufacturers less, less competition, make the market attractive injection and development potential of high technology content.
Hikma group's three core products are faced with different market
formation and growth drivers. Group makes full use of these different factors. Therefore, to obtain the very good performance. The diversification of regional production makes group in terms of production flexibility, improve its competitiveness in the international market. In addition, various sources of Hikma group of active pharmaceutical ingredients reduce the cost of raw materials and improve the profitability. At the same time, Hikma group in Northeast non area of strong sales ability make it become a partner in an ideal production license products. Attaches great importance to the quality of the group has been widely recognized, also makes the products of Hikma group in the MENA region on the market with other manufacturers of products in the region from.135 difference between professionals and scientists of the research team in Jordan and the United States R & D center, according to the needs of the market. The development of drugs in the pharmaceutical industry. Research and development plays a vital role, to ensure that the new products Everfount supply market, improve market share. As a part of the group's strategy, Hikma is ready to expand its research and development activities in Jordan, because labor and infrastructure costs about as much lower. However, in the United States R & D center will be the Hikma group the